Table 3. Univariate analysis of clinical characteristics, pathologic parameters, and genetic alterations with biochemical recurrence.
| Characteristic | Univariate analysis | |
|---|---|---|
| HR (95% CI) | p-value | |
| Age >65 years | 1.45 (0.45–4.66) | 0.53 |
| iPSA >20 | 0.77 (0.26–2.24) | 0.63 |
| Prostate volume (>50 mL) | 0.95 (0.04–0.63) | 0.01 |
| Pathologic Gleason grade group | 0.11 | |
| 3 | Reference | |
| 4–5 | 2.44 (0.83–7.20) | |
| Pathologic T stage | 0.49 | |
| T3a | Reference | |
| T3b | 1.46 (0.50–4.24) | |
| Positive surgical margin | 0.54 (0.18–1.64) | 0.28 |
| Pathologic N stage | 0.79 | |
| Intraductal carcinoma | 4.46 (0.78–25.41) | 0.09 |
| Perineural invasion | 2.00 (0.54–7.39) | 0.30 |
| BRAF mutation | 4.48 (1.32–29.09) | 0.03 |
| SPOP mutation | 1.87 (0.59–5.95) | 0.29 |
| KMT2D mutation | 1.14 (0.31–4.19) | 0.84 |
| ATM mutation | 0.55 (0.07–4.37) | 0.57 |
| FANCA mutation | 0.30 (0.04–2.30) | 0.25 |
| FANCD2 mutation | 0.82 (0.22–3.04) | 0.77 |
| FANCG mutation | 1.81 (0.46–7.10) | 0.40 |
| MAP3K1 mutation | 0.41 (0.05–3.19) | 0.40 |
| TSHR mutation | 0.57 (0.13–2.57) | 0.47 |
| ERG mutation | 0.45 (0.10–2.04) | 0.30 |
HR, hazard ratio; CI, confidence interval; iPSA, initial prostate-specific antigen.